4.7 Article

Limited sampling strategies for determining the area under the plasma concentration-time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis

期刊

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2017.01.036

关键词

Isoniazid; Drug exposure; Limited sampling strategy; Pharmacokinetics

向作者/读者索取更多资源

This study aimed to develop clinically feasible models of limited sampling strategy (LSS) for estimation of the area under the concentration-time curve (AUC(24h)) for isoniazid, that could be applied easily in daily clinical practice for dosage adjustment in adult patients with tuberculosis. Isoniazid plasma concentrations (n = 1665) from 185 adult tuberculous patients were used for the development and validation of LSS models to estimate AUC(24h) following administration of the standard 5 mg/kg dose of isoniazid. Population pharmacokinetic analysis for appropriate estimation of isoniazid pharmacokinetic parameters was performed in a modelling group (n = 100). The Bayesian estimates of AUC(24h) (AUC(ref)) obtained for each individual were used as the dependent variable in the regression analysis for the development of various LSS models. The LSS models were validated in a separate cohort (n = 85). Several three and four time point LSS models were built and tested. Model H (AUC(24h) = -1.88 + 1.05 x C-1 + 0.78 x C-2 + 9.44 x C-5) and Model I (AUC(24h) = -0.65 + 1.00 x C-1 + 1.94 x C-2 + 15.45 x C-9) had the best performances [adj-R-2 = 0.93, median prediction error (MPE) = -0.20, root median squared prediction error (RMSE) = 4.65 for Model H; adj-R-2 = 0.96, MPE = -0.05 RMSE = 3.56 for Model I]. The very high R-2 values (>= 0.94) of these regression equations in the validation cohort confirmed their high reliability. These LSS models could be applied in the context of therapeutic drug monitoring programmes aiming to personalize isoniazid dosing regimens for adult patients with tuberculosis. (C) 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Infectious Diseases

Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams

Milo Gatti, Federico Pea

Summary: This review evaluates the role of pharmacokinetic/pharmacodynamic (PK/PD) optimization of novel beta-lactams in the management of difficult-to-treat resistance (DTR) Gram-negative infections. The findings suggest that optimizing antimicrobial therapy with novel beta-lactams based on PK/PD concepts can maximize clinical efficacy and prevent resistance emergence. Establishing a coordinated multidisciplinary team and implementing personalized antimicrobial exposure optimization can be crucial for the management of DTR Gram-negative infections.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2023)

Article Pediatrics

Suicide attempts and eating disorders in adolescents, the mental health wave of the second year of the COVID-19 pandemic: A paediatric emergency department perspective

Giorgio Cozzi, Alberto Grillone, Elettra Zuliani, Manuela Giangreco, Chiara Zanchi, Giuseppe Abbracciavento, Egidio Barbi, Alessandro Amaddeo

Summary: This study compared adolescents' visits to a tertiary-level paediatric emergency department in Italy during the pre-pandemic year and the first and second years of the COVID-19 pandemic, focusing on mental health presentations. The results showed an increase in visits related to mental health problems in the second year of the pandemic, along with a sharp increase in suicide attempts and eating disorders.

FRONTIERS IN PEDIATRICS (2023)

Article Pharmacology & Pharmacy

Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections

Rossella Barone, Matteo Conti, Pier Giorgio Cojutti, Milo Gatti, Pierluigi Viale, Federico Pea

Summary: Dalbavancin (DBV) is a long-acting antistaphylococcal lypoglycopeptide increasingly used for long-term treatment of subacute and/or chronic infections. Population pharmacokinetic studies have shown that two 1500mg doses of DBV 1 week apart can effectively treat infections for weeks. This study developed and validated a fast and simple analytical method for measuring DBV concentrations in human plasma microsamples using Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry (ITD LC-MS/MS) technique.

PHARMACEUTICS (2023)

Article Microbiology

Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence

Milo Gatti, Bruno Viaggi, Gian Maria Rossolini, Federico Pea, Pierluigi Viale

Summary: Developing evidence-based algorithms for targeted antibiotic therapy in critically ill patients with Staphylococcus aureus infections was the objective of this study. By conducting literature searches and expert assessments, specific therapeutic options were proposed for different types of infections caused by methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

MICROORGANISMS (2023)

Article Microbiology

Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients

Pier Giorgio Cojutti, Aaron J. Heffernan, Thomas Tangden, Paola Della Siega, Carlo Tascini, Jason A. Roberts, Federico Pea

Summary: This study aimed to develop a population pharmacokinetic/pharmacodynamic (PK/PD) model of valganciclovir for preemptive therapy of cytomegalovirus (CMV) infection in kidney transplant patients. Ganciclovir concentrations and CMV viral loads were retrospectively obtained from kidney transplant patients. Monte Carlo simulations were conducted to assess the probability of attaining viral load targets, and a PK/PD model was devised.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Article Pharmacology & Pharmacy

Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients

Carla Troisi, Pier Giorgio Cojutti, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea

Summary: The aim of this study was to compare the daily dose of 24 h-continuous infusion meropenem when GFR was calculated using different equations. The results showed that using estimated GFR may lead to significant underestimation or overestimation of meropenem dosages, therefore dose adjustments should be based on measured creatinine clearance in critically ill patients.

PHARMACEUTICS (2023)

Article Pharmacology & Pharmacy

Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study

Chun Liu, Pier Giorgio Cojutti, Maddalena Giannella, Marcello Roberto, Beatrice Casadei, Gianluca Cristiano, Cristina Papayannidis, Nicola Vianelli, Pier Luigi Zinzani, Pierluigi Viale, Francesca Bonifazi, Federico Pea

Summary: CAR T-cell therapy may cause cytokine release syndrome (CRS) and acute kidney injury, potentially affecting the pharmacokinetics of beta-lactam drugs. This study found that the clearance of meropenem and piperacillin did not need to be reduced in CAR T-cell patients experiencing CRS.

PHARMACEUTICS (2023)

Article Infectious Diseases

Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis

Milo Gatti, Giacomo Fornaro, Zeno Pasquini, Andrea Zanoni, Michele Bartoletti, Pierluigi Viale, Federico Pea

Summary: This study investigated the impact of inflammation on voriconazole exposure in critically ill patients with COVID-associated pulmonary aspergillosis (CAPA). The results suggest that CRP values greater than 11.46 mg/dL and PCT values greater than 0.3 ng/mL may downregulate voriconazole metabolism and increase the risk of toxicity.

ANTIBIOTICS-BASEL (2023)

Article Infectious Diseases

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring

Rossella Barone, Matteo Conti, Beatrice Giorgi, Milo Gatti, Pier Giorgio Cojutti, Pierluigi Viale, Federico Pea

Summary: Meropenem (MRP)-Vaborbactam (VBR) is a novel beta-lactam/beta-lactamase inhibitor used for difficult-to-treat Gram-negative infections. Therapeutic drug monitoring (TDM) is necessary due to inter-individual variability. A fast and sensitive LC-MS/MS method was developed for quantifying MRP and VBR in 3 μL human plasma samples, and successfully applied to critically ill patients.

ANTIBIOTICS-BASEL (2023)

Article Microbiology

Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?

Milo Gatti, Matteo Rinaldi, Cecilia Bonazzetti, Paolo Gaibani, Maddalena Giannella, Pierluigi Viale, Federico Pea

Summary: This study aimed to assess the relationship between joint pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous infusion ceftazidime-avibactam and the microbiological outcome of difficult-to-treat resistant Gram-negative infections. The study found that optimized joint PK/PD target attainment could be a way to eradicate these infections and render combination therapy unnecessary.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Review Infectious Diseases

Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin

Alessandra Oliva, Francesco Giuseppe De Rosa, Malgorzata Mikulska, Federico Pea, Maurizio Sanguinetti, Carlo Tascini, Mario Venditti

Summary: Invasive Candida Infections (ICIs) have experienced significant changes in epidemiology, pathophysiology, and clinical manifestations in recent decades, including a shift towards non-albicans species and an increase in exogenous infections. The long-acting echinocandin rezafungin has shown potent in-vitro activity against Candida spp., including azole-resistant strains and C.auris.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2023)

Article Pharmacology & Pharmacy

The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan

Milo Gatti, Federico Pea

Summary: With the increasing spread of infections caused by multidrug-resistant pathogens, tailoring antimicrobial therapies based on a "patient-centered" approach is crucial. Therapeutic drug monitoring (TDM) is a valuable method, but expert interpretation of TDM results is needed to enhance clinical usefulness. MD Clinical Pharmacologists can interpret TDM results of antimicrobials in real-time for tailoring therapy based on specific drug/pathogen and patient issues.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2023)

Article Infectious Diseases

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections

Pasquale Maria Berrino, Milo Gatti, Matteo Rinaldi, Eugenio Brunocilla, Pierluigi Viale, Federico Pea

Summary: This study explores the relationship between pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous infusion (CI) piperacillin-tazobactam or meropenem monotherapy and microbiological outcome in urological patients with Gram-negative infections. The results demonstrate that optimizing beta-lactam treatment through real-time therapeutic drug monitoring (TDM)-guided expert clinical pharmacological advice (ECPA) program can achieve microbiological eradication in most cases.

ANTIBIOTICS-BASEL (2023)

Article Infectious Diseases

Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run

Milo Gatti, Pierluigi Viale, Federico Pea

Summary: This study aimed to assess the distribution of individual ceftazidime-to-avibactam ratios in relation to renal function in patients receiving continuous infusion ceftazidime/avibactam treatment. The results showed a wide interindividual variability in ceftazidime-to-avibactam ratios, supporting the view that both ceftazidime and avibactam concentrations should be measured to evaluate pharmacokinetic/pharmacodynamic target attainment.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Infectious Diseases

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections

Altea Gallerani, Milo Gatti, Andrea Bedini, Stefania Casolari, Gabriella Orlando, Cinzia Puzzolante, Erica Franceschini, Marianna Menozzi, Antonella Santoro, Nicole Barp, Sara Volpi, Alessandra Soffritti, Federico Pea, Cristina Mussini, Marianna Meschiari

Summary: This retrospective case series reports on the use of dalbavancin in the treatment of cardiovascular prosthetic infections. The results show that dalbavancin is effective and well-tolerated in this setting. Monitoring drug concentrations can individualize dosing and dosing intervals, further improving clinical outcomes.

ANTIBIOTICS-BASEL (2023)

Review Infectious Diseases

Lenacapavir: A novel injectable HIV-1 capsid inhibitor

Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman

Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)

Article Infectious Diseases

Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort

Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri

Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)